Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 20, 2011

Abbott to Distribute Biofortuna’s Freeze-Dried HLA-Typing PCR Kits

  • Molecular diagnostics firm Biofortuna inked an exclusive deal with Abbott’s molecular diagnostics business centered on distribution of the U.K. firm’s freeze-dried HLA-typing kits. Under terms of the deal Abbott will have exclusive distribution rights to the SSPGo kits worldwide, except in France, Spain, Portugal, and the Benelux countries. Abbott also has rights to distribute the associated interpretation software, Verdict, as well as kit updates. Biofortuna says the SSPGo HLA-typing kits are CE-marked, and will be available through Abbott outside the U.S in June. Submission to FDA for approval of the kits in the U.S. has been made.  

    Biofortuna’s products are based on what it claims is the world’s first freeze-dried PCR reaction mix. The resulting kits contain all necessary pre-dispensed buffers, primers & Taq, and require only the addition of DNA. The kits are stable at ambient temperatures for up to 16 months. The firm’s initial product line targets the SSP transplantation market, but the technology is also being harnessed to develop kits for blood grouping, disease identification, pharmacogenetic applications and HLA antibody screening. Verdict has been developed to accompany the SSPGo kits for results interpretation.

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »